SCIBASE AB

Company profile

About SCIBASE AB

SciBase AB is a global medical technology company specializing in early detection and prevention in dermatology. The company develops, manufactures, and commercializes Nevisense, a groundbreaking point-of-care platform that integrates AI (augmented intelligence) and advanced Electrical Impedance Spectroscopy (EIS) technology to improve diagnostic accuracy in skin cancer detection and skin disorder monitoring. Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, Nevisense represents a breakthrough in dermatological diagnostics. The platform applies harmless electrical signals to the skin to analyze cellular structure, size, and orientation—data not accessible through visual assessment methods. Nevisense is the world's first objective diagnostic support tool for non-visual detection of malignant melanoma, collecting 700 data points per measurement at frequencies between 1 kHz to 2.5 MHz. The non-invasive procedure provides clinicians with objective, actionable data at the point of care, enabling more confident diagnoses and reducing unnecessary biopsies. SciBase's mission is to ensure proactive skin health management and early detection of skin cancer and skin disorders, minimizing patient suffering while empowering clinicians to save lives through timely detection and intervention. The company serves dermatologists, healthcare professionals, and researchers globally, with applications spanning melanoma detection, keratinocyte cancer assessment, and skin barrier function research for both clinical and cosmetic testing purposes.

Company description · SCIBASE AB official website